贝达药业：公司团队正加紧准备申报材料，尽快递交恩沙替尼新增适应症的NDA申请

Core Viewpoint - The company is actively preparing to submit the NDA application for the new indication of Ensartinib, aiming to expedite the process to potentially meet the timeline for next year's national discussions [2]. Group 1 - Investors have inquired about the delay in submitting the post-operative adjuvant indication for Ensartinib [2]. - The company has confirmed that its team is working diligently to prepare the submission materials [2].